PhRMA’s 2012 Annual Meeting: “Welcome To The Patent Cliff”
Executive Summary
Gathering in Boston, the brand name trade association celebrates its search for solutions.
You may also be interested in...
Trump’s FDA Reform Agenda: Patient-Focused Approvals
A posting on the transition website takes a much milder tone than the GOP platform issued over the summer.
User Fee Bills: After Mark-ups, How Will House And Senate Reconcile Differences?
House and Senate committee user fee bill mark-ups approaching, but drafts have differences in drug shortage, supply chain security and other proposed policy changes to reconcile.
Amyvid Approval Just The Start Of A Critical Year For Alzheimer’s
One way or another, it is an important time in the Alzheimer’s disease space. Two potential disease altering therapies are set to divulge Phase III results that will answer important questions about the course of the illness, whether they are successful or not, and a promising cognition booster may get the Phase II readout it needs to head into a pivotal trial.